$7.99
0.50% today
Nasdaq, Apr 02, 10:00 pm CET
ISIN
US03152W1099
Symbol
FOLD
Sector
Industry

Amicus Therapeutics, Inc. Stock price

$7.95
-1.18 12.92% 1M
-2.71 25.42% 6M
-1.47 15.61% YTD
-3.80 32.34% 1Y
-1.48 15.69% 3Y
-0.91 10.27% 5Y
-3.04 27.66% 10Y
Nasdaq, Closing price Tue, Apr 01 2025
-0.21 2.57%
ISIN
US03152W1099
Symbol
FOLD
Sector
Industry

Key metrics

Market capitalization $2.44b
Enterprise Value $2.64b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 4.99
P/S ratio (TTM) P/S ratio 4.62
P/B ratio (TTM) P/B ratio 12.25
Revenue growth (TTM) Revenue growth 32.29%
Revenue (TTM) Revenue $528.30m
EBIT (operating result TTM) EBIT $34.06m
Free Cash Flow (TTM) Free Cash Flow $-37.44m
Cash position $249.95m
EPS (TTM) EPS $-0.18
P/E forward 277.56
P/S forward 3.87
EV/Sales forward 4.18
Short interest 5.71%
Show more

Is Amicus Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.

Amicus Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Amicus Therapeutics, Inc. forecast:

9x Buy
75%
3x Hold
25%

Analyst Opinions

12 Analysts have issued a Amicus Therapeutics, Inc. forecast:

Buy
75%
Hold
25%

Financial data from Amicus Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
528 528
32% 32%
100%
- Direct Costs 61 61
36% 36%
12%
467 467
32% 32%
88%
- Selling and Administrative Expenses 315 315
18% 18%
60%
- Research and Development Expense 109 109
28% 28%
21%
43 43
165% 165%
8%
- Depreciation and Amortization 8.55 8.55
9% 9%
2%
EBIT (Operating Income) EBIT 34 34
146% 146%
6%
Net Profit -56 -56
63% 63%
-11%

In millions USD.

Don't miss a Thing! We will send you all news about Amicus Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Amicus Therapeutics, Inc. Stock News

Neutral
Seeking Alpha
16 days ago
Amicus Therapeutics, Inc., with two approved rare disease therapies, shows strong revenue growth and market potential despite a 30% stock decline since 2021. Galafold and Pombiliti+Opfolda are driving revenue, with significant market share and potential label expansions, targeting $1bn revenue by 2028. The company has a solid financial position, minimal near-term competition, and a favorable pa...
Neutral
GlobeNewsWire
27 days ago
Hampton Dellinger v. Scott Bessent, Secretary of the Treasury, et al. Hampton Dellinger v. Scott Bessent, Secretary of the Treasury, et al.
Neutral
GlobeNewsWire
about one month ago
Texas Top Cop Shop, Inc., et al. v. Pamela Bondi, Attorney General of the United States, et al. Texas Top Cop Shop, Inc., et al. v. Pamela Bondi, Attorney General of the United States, et al.
More Amicus Therapeutics, Inc. News

Company Profile

Amicus Therapeutics, Inc. is a biotechnology company. It engages in the discovery, development, and commercialization of novel treatments for patients living with rare and orphan diseases. Its product includes migalastat HCl, which is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy for fabry disease. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ.

Head office United States
CEO Bradley Campbell
Employees 499
Founded 2002
Website www.amicusrx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today